
Iconix Pharmaceuticals Inc Profile last edited on: 5/5/17
CAGE: 3YVL6
UEI:
Business Identifier: Chemogenomics, chemoinformatics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
325 East Middlefield Road
Mountain View, CA 94043
Mountain View, CA 94043
(650) 567-5500 |
N/A |
N/A |
Location: Single
Congr. District: 18
County: Santa Clara
Congr. District: 18
County: Santa Clara
Public Profile
In 998, to extend its microbial genomics capability, publicly traded Microcide formed a separate genetics company, Iconix Pharmaceuticals, Using a toxicogenomics database of microarray and pharmacology data (DrugMatrixî) with the informatics expertise and computer skills required to mine and interpret this vast body of information, Iconixâs chemogenomic capabilities enable pharmaceutical companies to increase the odds of advancing the right compounds to the clinic, reducing attrition rates and the costs of drug discovery. Iconix Pharmaceuticals is among the first of its kind: a multi-disciplinary company that integrates the laboratory skills and knowledge necessary for the creation of the worldâs largest chemogenomics database of microarray and pharmacology data with the informatics expertise and computer skills required to mine and interpret this vast body of information.Iconix had focused these technologies on a line of chemogenomics products, services, and long-term collaborations. DrugMatrix® provides drug designers with a uniform source of chemogenomic information, analytical tools and data mining algorithms to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix will commercialize DrugMatrix through non-exclusive subscriptions sold to pharmaceutical and biotechnology companies. Based on the data in DrugMatrix, Iconix has mined out a library of Drug Signaturesâ¢, genomic patterns that are predictive of specific forms of toxicity and mechanisms of action. Iconix provides Pharmotif⢠Reports on specific customer compounds to chemogenomically classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix will also enter exclusive alliances with its research collaborators to apply its chemogenomics data and know how to customized drug discovery and development projects. Iconixâs therapeutic product programs are directed at new and important targets identified in genomic studies. The company employs DrugMatrix and Drug Signatures to prioritize its drug therapeutic candidates for further study. In August 2007, firm was acquired by Entelos - a firm developing computer models of disease intended to assist in the identification of drug candidates and early analysis of their effectiveness. Iconix had been focused on building âtoxicogenomicâ reference information, which details the genetic profiles that are most likely to lead to toxic side effects when a particular drug is used. It was suggested that he combination will create a new paradigm for discovering and developing drugs by making it possible to also predict whether certain drug candidates may cause tox
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
50-74Revenue Range
5M-7.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2004 | 1 | NIH | $97,654 | |
Project Title: Development of in vitro toxicity expression assays |
Key People / Management
Jim Neal -- Chief Executive Officer
Susanne Baumhueter
Richard Cording
Alan Engelberg -- Vice President of Marketing
Donald N Halbert -- Executive Vice President of Research and Development
Alan H Roter -- Vice President of Informatics
Cate Sabatini -- Executive Vice President of Business Development
Susanne Baumhueter
Richard Cording
Alan Engelberg -- Vice President of Marketing
Donald N Halbert -- Executive Vice President of Research and Development
Alan H Roter -- Vice President of Informatics
Cate Sabatini -- Executive Vice President of Business Development
Company News
Aug
30
2007
|
Entelos pays up to $39M for Iconix Biosciences |